EH Group Launches EH-TRACE 250kW Fuel Cell System
Decarbonising high power applications has never been easier. Following several years of intense development, EH Group is proud to launch its EH-TRACE M-250kW Fuel Cell System.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241028178580/en/
EH TRACE - 250kW Fuel Cell System (Photo: Business Wire)
A plug & play power solution featuring EH's advanced stack technology and AI/ML based control system. It offers unrivalled performance, versatility and cost reduction potential - based on our single stack platform EH-87 and single balance of plant. A fully integrated power module, it includes fuel cell system, heat exchanger and DC/DC for ease of implementation.
Modular in design, it can easily be configured for up to 3MW power in a standard 40ft container. Our uniquely simplified FC system architecture delivers a minimum electrical efficiency of >50%.
It has been developed for high power stationary applications such as data-centres, micro-grids and back-up power. Furthermore, it meets the challenging power needs and safety standards of the maritime sector and has already secured Approval In Principle from certification body DNV.
“The launch of EH-TRACE 250kW is a key milestone in the decarbonisation potential of our innovative fuel cell technology. Our team has designed a unique product that genuinely meets the operational requirements of large stationary and marine applications,” says Mardit Matian, EH Group Founder. “This opens up a new set of market opportunities to provide reliable CO2 free power to data centres, marine vessels, transport & logistics hubs, and many more,” added Christopher Brandon, co-Founder.
About EH Group
Established in Switzerland since 2017, EH Group is focused on the design and production of its innovative fuel cell technology. It offers unrivalled power density, greater system efficiency and a unique assembly process that radically reduces costs. It is aimed at the decarbonisation of heavy duty mobility, marine vessels, large stationary power and aviation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241028178580/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of AOC to Nippon Paint Holdings28.10.2024 12:00:00 CET | Press release
Lone Star Funds (“Lone Star”) today announces the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell AOC, a leading global specialty chemicals company, to Nippon Paint Holdings Co., Ltd. (“NPHD”). AOC is a leading manufacturer of specialty chemical formulations in the unsaturated polyester and vinyl ester sectors. With operations in North America, Europe and Asia, AOC serves customers globally in the infrastructure, construction (residential and commercial), transportation, and recreation sectors. Under Lone Star’s stewardship, AOC invested in its core business systems, including commercial excellence, innovation, procurement and manufacturing efficiency, to drive earnings growth. AOC also invested in the expansion of its executive leadership team, broadening the capabilities of the team to efficiently manage the global enterprise. AOC is poised to capitalize on its next leg of growth, supported by a well-capitalized asset base and a world-class manageme
Delta-Fly Pharma Inc.: Phase I/II Study of DFP-10917 and Venetoclax in AML Patients Begins with Promising Initial Data28.10.2024 12:00:00 CET | Press release
Following to the previous information on September 10th. 2024, we are excited to share our latest development status. Enrollment of patients is progressing smoothly into the Phase I portion of the Phase I/II study of DFP-10917 combined with Venetoclax in AML patients previously treated with Venetoclax, one regimen. The first three patients are showing encouraging safety and efficacy results suggested further promising development. The existing standard combination chemotherapy for AML patients is Azacitidine and Venetoclax, but it is not comfortable for AML patients. We’re trying to do a combination of DFP-10917 with Venetoclax, as an alternative safer AML therapy, objective NDA approval from the FDA in the US under possible collaboration with a global mega-pharma. The Phase III study of DFP-10917 in relapsed/refractory AML patients is planned data cut-off as decreasing in the number of long-term survivors since then. Please take notice of our own innovative approach for miserable canc
PMI Worldwide Brands, LLC (dba, Stanley 1913) Partners with Kinaxis to Strengthen Supply Chain28.10.2024 12:00:00 CET | Press release
Stanley 1913, a subsidiary of HAVI, aligns with supply chain orchestrator to meet ever-growing consumer demand Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, today announced that Stanley 1913 has selectedKinaxis to modernize its supply chain and ensure operational efficiencies to help ever-increasing consumer demand. Stanley 1913 innovates, designs and manufactures food and drinkware, including its iconic Quencher H2.0 FlowState™ Tumbler and innovative Stanley Cross Bottle. The global brand’s products are distributed in more than 60 countries worldwide. The Kinaxis Maestro™ platform will empower the Stanley 1913 team to sense potential supply chain hurdles quickly, analyze impacts and mitigation options, and implement rapid actions to address or prevent challenges that impact supply. “We have explored the use of advanced predictive analytics through machine learning and artificial intelligence, allowing us to gain end-to-end supply chain visibility
BeiGene Mourns Death of Beloved Board Member Donald Glazer28.10.2024 11:00:00 CET | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to share the news that Donald Glazer recently passed away. Don was a Board member and the chair of the nominating and corporate governance committee. Co-founder, Chairman and CEO John V. Oyler issued the following statement: “We are saddened by the passing of our dear friend, Don Glazer. He helped guide the founding of the company in 2010 and was an ardent supporter of our mission to deliver innovative medicines faster and more affordably to patients around the world. His impact from a professional and personal perspective is immeasurable, and he will be deeply missed by all of us who benefited from his extensive experience, sound judgment and wise counsel. We extend our heartfelt condolences to his family during this difficult time.” Mr. Glazer served as a passionate BeiGene Board member, building connections amongst broad networks of cancer doctors – including his own – around the world. He
Transition Industries LLC and Mitsubishi Gas Chemical announce Letter of Intent for a long-term Methanol Sales Agreement from the Pacifico Mexinol project in Sinaloa, Mexico28.10.2024 10:00:00 CET | Press release
Transition Industries LLC announced that it has signed a Letter of Intent (LOI) with Mitsubishi Gas Chemical Company, Inc. (MGC) to enter into a long-term Methanol Sales Agreement (MSA). Under the MSA, Transition Industries intends to supply MGC approximately 1 million MT per annum of ultra-low carbon methanol from its Pacifico Mexinol project, a 6,145 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico, expected to be in operation in 2028. Transition Industries is jointly developing Pacifico Mexinol with the International Finance Corporation (IFC), a member of the World Bank Group. The terms of the LOI and MSA were not disclosed. When it initiates operations, Pacifico Mexinol is expected to be the largest single ultra-low carbon chemicals facility in the world - producing approximately 350,000 MT of green methanol and 1.8 million MT of blue methanol annually from natural gas with carbon capture. Rommel Gallo, CEO of Transition Industries, commented: “We are pleas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom